FONT-SIZE Plus   Neg

Endocyte Reports DSMB Recommendations Following Interim Futility Analysis

Endocyte, Inc. (ECYT) unveiled the outcomes of the planned independent Data Safety Monitoring Board or DSMB review of the interim futility analysis for the Phase 2b TARGET study with investigational candidate vintafolide. The DSMB urged the continuation of the vintafolide combination therapy and docetaxel monotherapy arms of the trial.

In addition, the DSMB recommended investigators and patients be advised that vintafolide monotherapy is not likely to be declared superior to docetaxel in progression-free survival or PFS at the end of the study, and patients currently on vintafolide monotherapy may continue treatment based on guidance from their investigator. The TARGET trial's top-line results are expected in early 2014.

TARGET is being conducted in non-small cell lung cancer patients with all lesions expressing the folate receptor, as determined by the investigational companion imaging agent etarfolatide. This randomized trial is fully enrolled and comprised two investigational arms, vintafolide monotherapy and vintafolide in combination with docetaxel, each of which is compared to a standard of care control arm, docetaxel monotherapy.

The primary endpoint of the trial is PFS, powered to show a 50 percent improvement in PFS compared to the control arm, while secondary endpoints include the comparison of overall response rate, overall survival and safety.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
German conglomerate Bayer AG, which is in $66 billion deal to acquire U.S. seed firm Monsanto Co., on Wednesday raised its core earnings forecast for fiscal 2016 after reporting higher profit and sales in its third quarter. Further, the company maintained guidance for adjusted EBITDA, a key earnings metric, and sales. The stock is currently trading 3 percent lower in Germany. Aerospace and defense major Airbus Group SE Wednesday reported a decline in nine-month profit and new orders, while revenues were stable. The weak results reflected the ongoing ramp-up and transition from current to new aircraft models. Looking ahead, for fiscal 2016, the company continues to expect stable adjusted earnings per share and EBIT. Apple Inc. (AAPL) reported its third straight quarter of iPhone sales and revenue declines after the market closed on Tuesday. The tech giant's fourth-quarter profit trumped Wall Street expectations, while revenues fell short. Although, Apple reported its third straight year-over-year decline in iPhone...
comments powered by Disqus
Follow RTT